108 related articles for article (PubMed ID: 21206385)
1. Pharmacogenetic and germline prognostic markers of lung cancer.
Horgan AM; Yang B; Azad AK; Amir E; John T; Cescon DW; Wheatley-Price P; Hung RJ; Shepherd FA; Liu G
J Thorac Oncol; 2011 Feb; 6(2):296-304. PubMed ID: 21206385
[TBL] [Abstract][Full Text] [Related]
2. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
3. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics in cancer treatment.
Nagasubramanian R; Innocenti F; Ratain MJ
Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis.
Kiyohara C; Takayama K; Nakanishi Y
Lung Cancer; 2006 Dec; 54(3):267-83. PubMed ID: 16982113
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
7. Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cell carcinoma.
Kohno T; Kunitoh H; Mimaki S; Shiraishi K; Kuchiba A; Yamamoto S; Yokota J
J Thorac Oncol; 2011 Apr; 6(4):813-7. PubMed ID: 21623257
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
10. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
11. DNA repair gene X-ray repair cross complementing group 1 Arg194Trp polymorphism on the risk of lung cancer: a meta-analysis on 22 studies.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q; Lin H
J Thorac Oncol; 2010 Nov; 5(11):1741-7. PubMed ID: 20975374
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
Cortejoso L; López-Fernández LA
Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
[TBL] [Abstract][Full Text] [Related]
13. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
14. XRCC1 polymorphism and lung cancer risk.
Schneider J; Classen V; Helmig S
Expert Rev Mol Diagn; 2008 Nov; 8(6):761-80. PubMed ID: 18999926
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk.
Qian B; Zhang H; Zhang L; Zhou X; Yu H; Chen K
Lung Cancer; 2011 Aug; 73(2):138-46. PubMed ID: 21195504
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.
van Huis-Tanja LH; Ewing E; van der Straaten RJ; Swen JJ; Baak-Pablo RF; Punt CJ; Gelderblom AJ; Guchelaar HJ
Pharmacogenet Genomics; 2015 Jun; 25(6):279-88. PubMed ID: 25815774
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.
Wei HB; Lu XS; Shang LH; Xu G; Hu J; Che DH; Liu F; Wu Y; Zhang GM; Yu Y
Arch Med Res; 2011 Jul; 42(5):412-20. PubMed ID: 21827803
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M; Capelletti M; De Palma G; Franciosi V; Cavazzoni A; Mozzoni P; Alfieri RR; Goldoni M; Galetti M; Bortesi B; Bozzetti C; Loprevite M; Boni L; Camisa R; Rindi G; Petronini PG; Ardizzoni A
J Thorac Oncol; 2008 Oct; 3(10):1104-11. PubMed ID: 18827605
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic Predictors of Response.
Hertz DL; Rae JM
Adv Exp Med Biol; 2016; 882():191-215. PubMed ID: 26987536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
